Reviewing Aclarion (NASDAQ:ACON) and Firefly Neuroscience (NASDAQ:AIFF)

Firefly Neuroscience (NASDAQ:AIFF) and Aclarion (NASDAQ:ACON) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings and risk.

Valuation & Earnings

This table compares Firefly Neuroscience and Aclarion”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Firefly Neuroscience	$1.80 million	9.33	-$19.88 million	($0.59)	-1.81
Aclarion	$83,769.00	89.45	-$7.23 million	($7.40)	-0.35

Aclarion has lower revenue, but higher earnings than Firefly Neuroscience. Firefly Neuroscience is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Firefly Neuroscience and Aclarion’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Firefly Neuroscience	-506.23%	-90.17%	-72.05%
Aclarion	-10,948.81%	-59.34%	-56.12%

Volatility & Risk

Firefly Neuroscience has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Firefly Neuroscience and Aclarion, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Firefly Neuroscience	1	0	0	0	1.00
Aclarion	1	0	1	0	2.00

Aclarion has a consensus target price of $7.50, suggesting a potential upside of 188.46%. Given Aclarion’s stronger consensus rating and higher probable upside, analysts clearly believe Aclarion is more favorable than Firefly Neuroscience.

Insider and Institutional Ownership

5.0% of Firefly Neuroscience shares are held by institutional investors. Comparatively, 7.5% of Aclarion shares are held by institutional investors. 6.9% of Firefly Neuroscience shares are held by company insiders. Comparatively, 0.0% of Aclarion shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Aclarion beats Firefly Neuroscience on 10 of the 14 factors compared between the two stocks.

About Firefly Neuroscience

Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.